Table 3 Patients’ clinical outcomes classified according to ionized, total mg and fraction (iMg/tMg) concentrations (n = 500).

From: Prevalence, clinical characteristics, and health outcomes of dysmagnesemia measured by ionized and total body concentrations among medically hospitalized patients

By ionized Mg concentrations.

Characteristic

n (%) unless specified otherwise

Total

500 (100%)

≤ 0.46

mmol/L

17 (3.4%)

0.47–0.68 mmol/L

350 (70.0%)

≥ 0.69 mmol/L

133 (26.6%)

p-value

Length of stay, IQR, (Days)

4.54 (2.53–9.26)

4.7 (3.41–9.79)

4.54 (2.47–8.71)

4.51 (2.67–10.21)

0.60

Transfers to High Dependency Unit

116 (23.2%)

5 (29.4%)

76 (21.7%)

35 (26.3%)

0.46

Development of Ventricular Fibrillation after admission

3 (0.6%)

0

2 (0.57%)

1 (0.8%)

1.00

Development of Ventricular Tachycardia after admission

6 (1.2%)

0

4 (1.14%)

2 (1.2%)

0.73

Development of Atrial Fibrillation after admission

56 (11.2%)

4 (23.53%)

34 (9.71%)

18 (13.5%)

0.10

Cardiac arrest

46 (9.2%)

2 (11.8%)

29 (8.3%)

15 (11.3%)

0.56

Inpatient mortality

36 (7.2%)

0

25 (7.1%)

11 (8.3%)

0.46

90-day readmission

82 (16.4%)

2 (11.8%)

60 (17.1%)

20 (15.0%)

0.74

6-month all-cause mortality

63 (12.6%)

3 (17.7%)

40 (11.4%)

20 (15.0%)

0.46

By total Mg concentrations.

Characteristic

n (%) unless specified otherwise

Total

500 (100%)

≤ 0.69 mmol/L

66 (13.2%)

0.70-1.00 mmol/L

379 (75.8%)

≥ 1.01 mmol/L

55 (11.0%)

p-value

Length of stay, IQR, (Days)

4.47 (2.52–9.03)

5.33 (3.46–10.33)

4.35 (2.41–8.70)

4.51 (2.92–10.89)

0.12

Transfers to High Dependency Unit

116 (23.2%)

14 (21.2%)

81 (21.4%)

21 (38.2%)

0.02

Development of Ventricular Fibrillation after admission

3 (0.6%)

0

3 (0.8%)

0

1.00

Development of Ventricular Tachycardia after admission

6 (1.0%)

2 (1.06%)

4 (1.1%)

0

0.30

Development of Atrial Fibrillation (AF) after admission

56 (11.2%)

7 (10.6%)

41 (10.8%)

8 (14.6%)

0.69

Cardiac arrest

46 (9.2%)

6 (9.1%)

29 (7.7%)

11 (20.0%)

0.01

Inpatient mortality

36 (7.2%)

4 (6.1%)

26 (6.9%)

6 (10.9%)

0.51

90-day readmission

82 (16.4%)

11 (16.7%)

58 (15.3%)

13 (23.6%)

0.29

6-month all-cause mortality

63 (12.6%)

6 (9.09%)

44 (11.6%)

13 (23.6%)

0.03

By fraction (iMg/tMg) concentrations.

Characteristic

n (%) unless specified otherwise

Total

500 (100%)

≤ 60%

19 (3.8%)

61–80%

335 (67.0%)

≥ 81%

146 (29.2%)

p-value

Length of stay, IQR, (Days)

4.47 (2.52–9.03)

3.24 (1.77–6.40)

4.50 (2.54–8.75)

4.57 (2.66–10.20)

0.22

Transfers to High Dependency Unit

116 (23.2%)

11 (57.9%)

70 (20.9%)

35 (24.0%)

< 0.01

Development of Ventricular Fibrillation after admission

3 (0.6%)

0

2 (0.6%)

1 (0.7%)

0.94

Development of Ventricular Tachycardia after admission

6 (1.2%)

0

3 (0.9%)

3 (2.1%)

0.49

Development of Atrial Fibrillation (AF) after admission

56 (11.2%)

2 (10.5%)

41 (12.2%)

13 (8.9%)

0.56

Cardiac arrest

46 (9.2%)

7 (36.8%)

29 (8.7%)

10 (6.9%)

< 0.01

Inpatient mortality

36 (7.2%)

7 (36.8%)

15 (5.4%)

11 (7.5%)

< 0.01

90-day readmission

82 (16.4%)

3 (15.8%)

58 (17.3%)

21 (14.4%)

0.73

6-month all-cause mortality

63 (12.6%)

9 (47.4%)

41 (12.2%)

13 (8.9%)

< 0.01

Back to article page